Plain-English translation of NCT06992648 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether trifluridine/tipiracil combined with regorafenib works as well as trifluridine/tipiracil combined with bevacizumab for people with advanced colorectal cancer that has not responded to earlier treatments. You would be randomly assigned to receive one of these two medication combinations, and the study team would track how well the treatment works and what side effects you experience.
Colorectal cancer that comes back or stops responding to standard treatments is very difficult to manage, and doctors need better options. This study is testing whether the new combination might be just as effective as the current standard approach, which could give patients another hope for treatment.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic regularly to receive the medication—one group takes oral tablets at home twice daily for 5 days every 2 weeks, while the other group takes oral tablets plus receives an intravenous infusion every 2 weeks. You would have blood tests and scans to monitor how well the treatment is working and watch for side effects. This continues until your cancer progresses, side effects become too difficult, or the study ends, with follow-up check-ins every 8 weeks after you stop treatment.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China